MattyEC

If there's an additional benefit to personalizing migraine treatment, then I'm curious what pre-clinical or clinical research has been performed that supports the ability of gene markers to prognose and elucidate the importance of various risk factors or interventions when treating migraines.

.

Wouldn't your team's ability to better treat migraines also depend on the type of migraine and markers you employ? (e.g. do basilar migraine with vertiginous components share the same informative risk alleles as migraines with classical profiles?)

As a result, I'm curious if there are specific types of migraines you're initially focusing on and if an early consultation helps your team identify whether a patient is suitable for your approach.

I've seen the CDC note how an mRNA vaccine's payload would never even enter the nucleus, and by virtue of being mRNA, one would expect little possibility of it ever integrating into our DNA genome, especially given its incredibly short half life.

How do DNA vaccines like JNJ's account for the potential risk inherent in an exogenous DNA segment being translocated into the nucleus, having the same inherent nature of our genome, and being significantly more stable than mRNA?